{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000056","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.374777+00:00","generated_at":"2026-05-30T02:18:58.933517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mineralys Q3 net loss widens to $56.3M; pivotal trial enrollments complete, data due H1 2025","bullets":["Net loss of $56.3M for Q3 2024 vs $22.8M in Q3 2023; R&D expense rose to $54.0M from $22.5M.","Cash & investments $263.6M; company believes sufficient to fund operations into 2026.","Advance-HTN pivotal trial fully enrolled; topline data expected March 2025.","Launch-HTN Phase 3 trial enrolled ahead of schedule; topline data anticipated mid first half 2025.","Explore-CKD Phase 2 trial enrollment ongoing; topline data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000056","json":"https://secwatch.observer/filing/0001933414-24-000056.json","markdown":"https://secwatch.observer/filing/0001933414-24-000056.md","text":"https://secwatch.observer/filing/0001933414-24-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/0001933414-24-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys-20241111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:18:58.933517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}